Form 4: Regeneron Pharmaceuticals CFO Reports Stock Transaction
Insider Transaction (Form 4)
Christopher R. Fenimore, EVP Finance CFO of Regeneron Pharmaceuticals, Inc., reported multiple transactions in common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 6,283 Common Stock at $381.92 ($2,399,603) on August 18, 2026; holds 24,583 after (Direct).
- Tax/exercise-price withholding: disposed of 4,599 Common Stock at $813.47 ($3,741,149) on August 18, 2026; holds 19,984 after (Direct).
- Option exercise/conversion: disposed of 6,283 Non-Qualified Stock Option (right to buy) on August 18, 2026; holds 6,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Christopher R. Fenimore — Officer (EVP Finance CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock | 6,283 | $382 | $2.4M | 24,583 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 4,599 | $813 | $3.7M | 19,984 |
| 2026-08-18 | Option exercise/conversion | Non-Qualified Stock Option (right to buy) | 6,283 | — | — | 6,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (6,283 shares) |
| 2026-08-18 | Tax/exercise-price withholding (4,599 shares) |
| 2026-08-18 | Option exercise/conversion (6,283 shares) |
Keywords
insider transaction, Form 4, REGN, REGENERON PHARMACEUTICALS, INC., neutral, Christopher R. Fenimore
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.